News
Dr. Sean Kerby First Patient Screened Studywide in an Obesity & T2DM Trial
Congratulations to Dr. Sean Kerby and the DelRicht clinical research team at Gulfport Memorial Hospital for the achievement of the first patient screened studywide in a major obesity and Type 2 Diabetes Mellitus (T2DM) trial. This U.S. trial evaluates the efficacy of an oral treatment for weight management in adults...
New JID Vitiligo Publication Features Dr. Ira Thorla as Contributing Author
Vitiligo Treatment Advancement Exciting progress continues to emerge in the ongoing effort to advance nonsegmental vitiligo research, particularly in evaluating how combining narrow-band UVB (NB-UVB) phototherapy with topical Janus kinase (JAK) inhibitors can safely accelerate repigmentation and prevent premature treatment discontinuation. As the dermatology landscape shifts toward more nuanced, multi-modality...
DelRicht Research Enrolls 232.7% of Enrollment Goal in Phase 2 Hidradenitis Suppurativa Trial
Advanced dermatology protocols require more than just standard site execution; they demand precise data and response-guided care. As clinical pipelines increasingly prioritize complex immunological conditions like Hidradenitis Suppurativa (HS), DelRicht Research distinguishes itself as a high-speed partner for sponsors and CROs. By pairing data-driven recruitment with agile infrastructure, our network...
Dr. Patrick Dennis Achieves First Patient Randomized in an Osteoarthritis of the Knee Trial
NEW ORLEANS, LA – Congratulations to Dr. Patrick Dennis and the exceptional clinical research team at Touro Medical Center for achieving the first site activated, first patient screened, and enrolled in a global Phase IIb clinical trial. This trial evaluates for the treatment of patients suffering from age-related primary moderate-to-severe...
95.6% Retention Rate Achieved in Phase 3 Type 2 Diabetes & Obesity Trial
In the rapidly evolving landscape of metabolic health, the demand for high-quality, reliable data in Type 2 Diabetes (T2DM) and obesity trials has never been greater. DelRicht Research has proven to be a cornerstone partner for T2DM and obesity clinical trials. By combining aggressive recruitment strategies with a streamlined operational...
DelRicht Research Enrolls 159.49% of Expected Goal in Phase 3 Obesity Trial
As the clinical focus shifts toward the growing complexities of chronic weight management, the demand for high-quality, reliable data in obesity trials has never been greater. DelRicht Research has proven to be a cornerstone partner for sponsors navigating the complexities of chronic weight management and its associated comorbidities. By combining...
Delivering Expertise and Enrollment Success in Cardiometabolic Research
Cardiometabolic research stands at the intersection of some of the most complex and prevalent health challenges of our time. From the rising tide of obesity and metabolic-associated steatohepatitis (MASH) to the persistent burden of Type 2 Diabetes Mellitus (T2DM) and hypertension, trials in this space require more than just patient...
Dr. Patrick Dennis Contributes to Herpes Zoster Research Published in CID
NEW ORLEANS, LA – Exciting progress continues to emerge in the ongoing effort to advance Herpes Zoster vaccine research, particularly in co-administration of RSVPreF3 and RZV and how it could improve vaccine coverage and reduce the number of vaccination visits for adults older than 50 years of age. Among the...
DelRicht Enrolls 126% of Expected Enrollment in a Phase 3 Pneumococcal Vaccine Trial
Selected as a participating site network for a Phase 3 Pneumococcal Vaccine trial, DelRicht Research was entrusted with enrolling healthy, pneumococcal-naïve adults across two specialized sites. From challenges including strict “pneumococcal-naïve” verification requirements for older populations and the technical barriers of 24-hour eDiary windows, DelRicht Research delivered through refined intake...
Proven Success in Psoriasis Trials: The DelRicht Difference
As the psoriasis landscape shifts toward targeted biologics and innovative topicals, DelRicht Research offers sponsors a premier partnership built on operational excellence. With 14 psoriasis trials completed, 130+ participants enrolled, and 8 experienced sites nationwide, our embedded network delivers high-quality data and rapid enrollment for even the most complex dermatology...
